Growth Equity Opportunities Fund IV, LLC 13D and 13G filings for Addex Therapeutics Ltd:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-08-14 8:12 pm Sale |
2024-08-12 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-6,624,600 (Position Closed) |
Filing |
| 2024-08-05 9:00 pm Sale |
2024-08-01 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 6,624,600 5.100% |
-1,080,000 (-14.02%) |
Filing |
| 2023-12-08 2:11 pm Purchase |
2023-11-27 | 13D | Addex Therapeutics Ltd ADXN |
Growth Equity Opportunities Fund IV, LLC | 7,704,600 6.400% |
7,704,600 (New Position) |
Filing |